TY - JOUR
T1 - Enhancement of clonogenicity of human multiple myeloma by dendritic cells
AU - Kukreja, Anjli
AU - Hutchinson, Aisha
AU - Dhodapkar, Kavita
AU - Mazumder, Amitabha
AU - Vesole, David
AU - Angitapalli, Revathi
AU - Jagannath, Sundar
AU - Dhodapkar, Madhav V.
PY - 2006/8/7
Y1 - 2006/8/7
N2 - Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245-252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor-DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention. JEM
AB - Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245-252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor-DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention. JEM
UR - http://www.scopus.com/inward/record.url?scp=33746912289&partnerID=8YFLogxK
U2 - 10.1084/jem.20052136
DO - 10.1084/jem.20052136
M3 - Article
C2 - 16880256
AN - SCOPUS:33746912289
SN - 0022-1007
VL - 203
SP - 1859
EP - 1865
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 8
ER -